showed a trendp = 0.0596
A recent randomized controlled trial of 36 TA patients in remission assigned to placebo or the novel interleukin-6 receptor antagonist tocilizumab showed a trend toward increased time to relapse without reaching significance (p = 0.0596) ( 7 ).